Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. - Wikidata - wikimedia - TriplyDB

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

http://www.wikidata.org/entity/Q41080467

about

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Inhibition of neuroblastoma tumor growth by targeted delivery of microRNA-34a using anti-disialoganglioside GD2 coated nanoparticles Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients.Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index Post-transplant immunotherapy designed to prevent cancer recurrence.Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins.A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Murine models for experimental therapy of pediatric solid tumors with poor prognosis.Close interactions between mesenchymal stem cells and neuroblastoma cell lines lead to tumor growth inhibition.Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study.Antibody-based immunotherapy in high-risk neuroblastoma.Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.Chimeric antibody c.8B6 to O-acetyl-GD2 mediates the same efficient anti-neuroblastoma effects as therapeutic ch14.18 antibody to GD2 without antibody induced allodynia Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma.Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.Integrin α4 Enhances Metastasis and May Be Associated with Poor Prognosis in MYCN-low Neuroblastoma.Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma.Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention.Activation of preexisting T cell clones by targeted interleukin 2 therapy.In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy Phase II trial of hu14.18-IL2 for patients with metastatic melanoma.Immunotherapy of neuroblastoma: present, past and future.Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy.Disialoganglioside directed immunotherapy of neuroblastoma.RESEARCH ADVANCES IN NEUROBLASTOMA IMMUNOTHERAPY.Intratumoral immunocytokine treatment results in enhanced antitumor effects.Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments.Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma.Current and Potential Uses of Immunocytokines as Cancer Immunotherapy.ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.DNA vaccination: using the patient's immune system to overcome cancer Immunocombination therapy for high-risk neuroblastoma.Chemokine-based immunotherapy: delivery systems and combination therapies.Advances and challenges in developing cytokine fusion proteins as improved therapeutics.Immunocytokines: a review of molecules in clinical development for cancer therapy.

P2860

Q26797345-F2BECE17-AA74-4019-9933-C25EB01799D6 Q27301841-203BF88F-6B33-43EE-BCE0-520B8FD0F614 Q33363235-5F771E9D-B8D0-4F5D-BF8E-61E5C870EDD8 Q33718131-965621E1-2A1C-48A8-A97F-5845BE52588A Q33788224-B144F640-6290-4779-B9DA-F67F982FDD84 Q33997679-6AFAD684-7680-4BFA-BB33-48AD2F0D7CF2 Q34038079-ABD47407-738B-4191-BE26-A53F9418DA89 Q34186886-D2285D41-2DE6-4D71-8FD0-963ED0DCD2A2 Q34210418-6D170314-214D-4F44-836F-AD23CF9CD849 Q34465378-B0F173E9-7212-474E-BB00-05DC64A275AA Q34488726-3A640B01-56CF-41DA-B6D0-EC659A0297E8 Q34725758-E59E7F33-EF39-4F0C-B40A-5E495AB56B6A Q34756781-037C593A-DAE4-4B5E-8A50-184679E0EDF7 Q35031732-3B954937-5CCD-4A5C-8D62-E47D17E01EC8 Q35092616-F88CFB58-57CC-4155-B61C-67FAC9D310C4 Q35308393-D63C64DA-D663-4906-9409-BE10C219E448 Q35556712-C739430F-D711-4B90-9A14-D31C890F8AB7 Q35631506-13BA6B6D-B696-4C71-87E3-7E823B4A0327 Q35747067-3625485B-7478-4343-8686-775221ACF522 Q35922239-34694349-739F-420E-9EF5-0AF68CC376C5 Q35953824-50C965DA-54F2-42A2-A94F-5CDF91D5F0FB Q36179663-77319471-F794-4551-B457-9F64D1D05B9E Q36219989-48A0243A-DB4F-499A-B4CC-5338ED4C3C4F Q36314064-9924BC0D-8F22-4488-A18E-269766264894 Q36412879-6BBC884C-7D71-4D73-BB6E-ACB56F3E42E7 Q36453273-0F6C6846-72D5-4193-B952-D0B096196BAA Q36751440-442B4E85-CA07-48DB-A702-504181B559ED Q36761416-EAE19ABA-4F14-48BD-BE01-A2C2895261CF Q36776358-C143ADC1-3AAC-4B9A-B2DA-4D2C057E4D57 Q36953492-CB43E4AE-8123-4B72-862F-0B4480835197 Q37038652-26BF8A56-3AC7-4062-BC4D-050793523F73 Q37059790-ED92D1B8-6ADC-44F0-8D8A-4227CD151B41 Q37328301-C41984A9-BA6C-4F37-9565-2570EB8935C6 Q37637949-427349FB-98B6-4498-8C6A-8E0965482461 Q37680218-D99483F9-82B6-4BF0-B57D-03174E4BE27C Q37825422-AF88AA92-743D-4EAA-A771-AB1ABD708116 Q37991024-A4C62065-2E76-44A8-A3E8-0C839CE6B5C1 Q38040509-FF697C0D-15E8-46BA-9D06-0C60A57B1870 Q38088357-7686A73E-9461-4295-859F-1D27DD28A03E Q38132742-CE9EE9B1-65B1-43F1-8806-1E80A4368BA2

P2860

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

http://www.wikidata.org/entity/Q41080467

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

1997年论文

@zh

1997年论文

@zh-cn

name

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

@en

type

label

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

@en

prefLabel

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

@en

P1433

Q41080467-26D5B9F6-6C10-4AFA-B40B-CF0FEA2F5CD7

P1476

Q41080467-A967F3FC-9370-418D-8CA6-02F3B2A66173

P2093

Q41080467-0678BBB5-0D33-412F-B071-5A66B7587613

Q41080467-6055DD8A-6DA2-45C5-A926-DF62DFE1BA4B

Q41080467-6914A50C-2C70-47B9-8AEB-ACE848854B05

Q41080467-7C09975C-7E3E-48FD-82CA-1DDAC1F37441

Q41080467-B052801D-63C2-4643-95E3-781633D3DAD1

Q41080467-B9DD5D54-48A7-4FFB-98FE-9C7ECD1141BE

P304

Q41080467-36FF7507-2B74-4199-ACE8-F04BBF9591BD

P31

Q41080467-43A5A733-64C4-4908-9928-39127FD6F315

P356

Q41080467-E5196C6D-517C-4B61-8709-19C67BE70FF8

P407

Q41080467-6E11E9C3-8AA0-4D53-BF01-00BE9E1F84FE

P433

Q41080467-762F440F-C9A0-4CF5-A929-3D3FC60BD8A4

P478

Q41080467-D8E5A0C0-5766-46EC-A127-78806AA75C5A

P577

Q41080467-1EF3439C-451A-49D5-895B-8949A2336D68

P5875

Q41080467-2986BF59-C34A-4D4C-AC33-91C814D0E0FA

P698

Q41080467-2D30E5EF-CECB-4EB9-955B-FFC0ADFEF8FE

P356

P1433

Journal of the National Cancer Institute

P1476

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.

@en

P2093

Dolman CS

http://www.w3.org/2001/XMLSchema#string

Gillies SD

http://www.w3.org/2001/XMLSchema#string

Lode HN

http://www.w3.org/2001/XMLSchema#string

Reisfeld RA

http://www.w3.org/2001/XMLSchema#string

Varki NM

http://www.w3.org/2001/XMLSchema#string

Xiang R

http://www.w3.org/2001/XMLSchema#string

P304

1586-1594

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/89.21.1586

http://www.w3.org/2001/XMLSchema#string

P407

P433

21

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

1997-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13868016

http://www.w3.org/2001/XMLSchema#string

P698

9362156

http://www.w3.org/2001/XMLSchema#string